Exact Sciences Co. (NASDAQ:EXAS) Shares Purchased by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. raised its position in Exact Sciences Co. (NASDAQ:EXAS) by 14.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 8,582 shares of the medical research company’s stock after purchasing an additional 1,073 shares during the period. J.W. Cole Advisors Inc.’s holdings in Exact Sciences were worth $482,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Chicago Partners Investment Group LLC lifted its position in Exact Sciences by 1.7% during the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock worth $651,000 after buying an additional 158 shares during the period. Perigon Wealth Management LLC lifted its position in Exact Sciences by 3.2% during the fourth quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock worth $474,000 after buying an additional 264 shares during the period. Huntington National Bank lifted its position in Exact Sciences by 838.1% during the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after buying an additional 352 shares during the period. CIBC Asset Management Inc lifted its position in Exact Sciences by 6.1% during the third quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company’s stock worth $442,000 after buying an additional 371 shares during the period. Finally, Advisors Asset Management Inc. lifted its position in Exact Sciences by 1.4% during the third quarter. Advisors Asset Management Inc. now owns 28,650 shares of the medical research company’s stock worth $1,952,000 after buying an additional 402 shares during the period. Institutional investors and hedge funds own 88.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on EXAS. Citigroup reduced their target price on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Stifel Nicolaus cut their price objective on Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. TD Cowen raised their price objective on Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Sanford C. Bernstein raised their price objective on Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Finally, Bank of America cut their price objective on Exact Sciences from $75.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, December 13th. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $72.76.

Exact Sciences Price Performance

Shares of EXAS opened at $50.48 on Thursday. The firm has a market cap of $9.34 billion, a price-to-earnings ratio of -43.14 and a beta of 1.24. The stock has a 50 day moving average of $55.41 and a 200-day moving average of $60.10. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. Exact Sciences Co. has a 52 week low of $40.62 and a 52 week high of $79.62.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. As a group, analysts forecast that Exact Sciences Co. will post -1.1 EPS for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.